Long-term outcomes and prognostic risk factors in patients recovered from hepatitis B virus related acute-on-chronic liver failure
10.3760/cma.j.issn.1003-9279.2017.02.012
- VernacularTitle: 乙型肝炎病毒相关慢加急性肝衰竭恢复患者的长期预后
- Author:
Hong ZANG
1
;
Long XIAO
2
;
Wanshu LIU
2
;
Hongling LIU
1
;
Bing ZHU
2
;
Shaoli YOU
2
;
Shaojie XIN
2
Author Information
1. Liver Transplantation Center, No.302 Hospital of PLA, Beijing 100039, China
2. Liver Failure Treatment and Research Center, No.302 Hospital of the People′s Liberation Army(PLA), Beijing 100039, China
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Acute-on-chronic liver failure;
Prognosis, Risk factors
- From:
Chinese Journal of Experimental and Clinical Virology
2017;31(2):137-141
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the long-term prognosis of the convalescent patients with hepatitis B virus (HBV) associated acute-on-chronic liver failure (HBV-ACLF).
Methods:A 72-month follow-up study of HBV-ACLF recovery patients recruited between January 2005 and December 2009 was performed in our hospital. According to the results of imaging examination at the first visit, the enrolled patients were divided into two groups, the liver cirrhosis ACLF (Lc-ACLF) group and chronic hepatitis B related ACLF (CHB-ACLF) group. In both groups, the occurrence of cirrhosis, decompensated cirrhosis or ACLF and hepatocellular carcinoma (HCC) were observed.
Results:The media time of cirrhosis formation, decompensated cirrhosis and HCC occurrence in CHB-ACLF group were 12.5, 23 and 43 months, respectively. However, the median time of LC-ACLF patients developing to decompensated cirrhosis and HCC were 7 and 14 months, which was significantly shorter than that in CHB-ACLF group (P=0.009, 0.040, with statistical significance). Furthermore, the blood chemical parameters including serum albumin (ALB), cholinesterase (CHE) and total cholesterol (TC), triglyceride (TG), as well as platelet count (PLT), the anti-viral treatment compliance and the virus mutation were significantly related to the clinical endpoint events, respectively (P<0.05). Moreover, results from the logistic regression model demonstrated that the patient age, with or without liver cirrhosis, HBV mutation and the anti-viral treatment compliance were the independent risk factors for the long-term prognosis of patients with hepatitis B associated liver failure (OR=1.035, 0.510, 2.462, respectively. P< 0.05). The cumulative risk of Lc-ACLF patients progressed to decompensate cirrhosis, acute-on-chronic liver failure or HCC was significantly higher than that of CHB-ACLF patients (χ2=21.603, 4.423, P=0.000, 0.035, respectively).
Conclusions:Considering the importance of patients with or without liver cirrhosis, HBV mutation and the anti-viral treatment compliance in the long-term prognosis of HBV-ACLF patients, it is necessary and important to monitor the virus mutation and anti-viral treatment compliance of HBV- ACLF patients during antiviral therapy and those processes would benefit the improvement of long term prognosis of the patients with ACLF.
